JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

Benzinga Newsdesk www.benzinga.com Positive 70.3%

Neg 0% Neu 0% Pos 70.3%

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $50 to $58.